Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe current standard of care in the first line is a combination of Genentech’s Herceptin...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoGets Under Your Skin Halozyme Therapeutics is an expert in drug delivery. The company is known for...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 4 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 5 days agoThis randomised trial, conducted across 85 centres in China, compared Ambrx Biopharma’s antibody-...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 4 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via Yahoo News· 6 days agoThe findings, presented in Chicago at the annual meeting of the American Society of Clinical...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 6 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference ...
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Zacks via Yahoo Finance· 3 days agoThe outlook for 2024 is ordinary as well. Competition from biosimilars for established cancer...